ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ADMA BIOLOGICS, INC. (ADMA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [e-mail], by telephone at [phone] or visit our website at www.howardsmithlaw.com.

What Happened?

On March 24, 2026, Culper Research published a report alleging “Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” Among other things, the report stated that “two high-level employees at one of ADMA's two largest distributors,” had confirmed independently that “starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.”

On this news, ADMA’s stock price fell $3.96, or 29.1%, over two consecutive trading days to close at $9.63 per share on March 25, 2026, thereby injuring investors.

Contact Us to Participate or Learn More:

If you purchased ADMA securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, Pennsylvania 19020
Telephone: [phone]
Email: [e-mail]
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420037972/en/

The ADMA Biologics Stock at the time of publication of the news with a raise of +0,73 % to 11,09USD on Nasdaq stock exchange (20. April 2026, 23:34 Uhr).